All In Biotech

Drug Trial Radar · NCT02132988

Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer

An Open Labeled Phase II Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Last checked: Nov 19, 2026Latest source record: May 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

110

Planned (sponsor's estimate)

Start

Nov 2013

Primary completion

Nov 2017

Study completion Nov 2018

Sponsor

Lead sponsor
Mackay Memorial HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
OBI Pharma, Inc
First posted
May 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of OPT-822/OPT-821 on improving Progression-Free Survival (PFS) in subjects who have non-progressive epithelial ovarian, fallopian tube, or primary peritoneal cancer after cytoreductive surgery and platinum-based chemotherapy as initial treatment for primary disease or as salvage treatment for first relapse.

Conditions

  • Ovarian Cancer

Interventions

  • OPT-822/OPT-821Biological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Until disease progression or up to 5 years after the enrollment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mackay Memorial Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.